- Home
- VRDN vs BHVN Comparison
VRDN vs BHVN Comparison
Compare VRDN & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- BHVN
- Stock Information
- Founded
- VRDN 2006
- BHVN 2013
- Country
- VRDN United States
- BHVN United States
- Employees
- VRDN N/A
- BHVN N/A
- Industry
- VRDN Medical Specialities
- BHVN Biotechnology: Pharmaceutical Preparations
- Sector
- VRDN Health Care
- BHVN Health Care
- Exchange
- VRDN Nasdaq
- BHVN Nasdaq
- Market Cap
- VRDN 1.6B
- BHVN 1.9B
- IPO Year
- VRDN N/A
- BHVN 2017
- Fundamental
- Price
- VRDN $13.13
- BHVN $20.37
- Analyst Decision
- VRDN Buy
- BHVN Strong Buy
- Analyst Count
- VRDN 12
- BHVN 14
- Target Price
- VRDN $36.44
- BHVN $63.15
- AVG Volume (30 Days)
- VRDN 1.2M
- BHVN 1.7M
- Earning Date
- VRDN 05-07-2025
- BHVN 05-08-2025
- Dividend Yield
- VRDN N/A
- BHVN N/A
- EPS Growth
- VRDN N/A
- BHVN N/A
- EPS
- VRDN N/A
- BHVN N/A
- Revenue
- VRDN $302,000.00
- BHVN N/A
- Revenue This Year
- VRDN N/A
- BHVN N/A
- Revenue Next Year
- VRDN $20,553.29
- BHVN $65.26
- P/E Ratio
- VRDN N/A
- BHVN N/A
- Revenue Growth
- VRDN N/A
- BHVN N/A
- 52 Week Low
- VRDN $9.90
- BHVN $15.79
- 52 Week High
- VRDN $27.20
- BHVN $55.70
- Technical
- Relative Strength Index (RSI)
- VRDN 46.75
- BHVN 39.78
- Support Level
- VRDN $9.90
- BHVN $15.79
- Resistance Level
- VRDN $14.22
- BHVN $19.30
- Average True Range (ATR)
- VRDN 1.17
- BHVN 2.20
- MACD
- VRDN 0.18
- BHVN 0.26
- Stochastic Oscillator
- VRDN 74.77
- BHVN 42.84
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.